Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPBATISTA, M. V.COSTA, S. F.SHIKANAI-YASUDA, M. A.MOSS, R. B.2013-09-232013-09-232013DRUGS OF TODAY, v.49, n.3, p.213-226, 20131699-3993https://observatorio.fm.usp.br/handle/OPI/1967Invasive pulmonary aspergillosis is a major cause of morbidity and mortality in immunocom promised patients, particularly those with hematological malignancies in the setting of profound neutropenia and/or hematopoietic stem cell transplant recipients. The optimal therapy for invasive aspergillosis relies on the restoration of leukocyte counts and effective antifungal treatment initiated at the earliest stage of infection. Several alternative antifungal compounds are currently available. A rational approach should take into account not only the degree of certainty of infection (as codified by the EORTC/MSG classification), but also previous exposure to other antifungals, the pharmacokinetic and pharmacodynamic characteristics of the antifungals employed and the clinical characteristics of the patient.engrestrictedAccessInvasive aspergillosisAntifungal therapyAntifungal drugsVoriconazoleCaspofunginAmphotericin BImmunocompromised hostsPolyene antibioticsAzolesEchinocandinsInvasive fungal infectionliposomal amphotericin-bempirical antifungal therapyhematopoietic-cell transplantationfungal-infectionsimmunocompromised patientscolloidal dispersionneutropenic patientspersistent feverdouble-blindhematologic malignanciesarticleCopyright PROUS SCIENCE, SAU-THOMSON REUTERS10.1358/dot.2013.49.3.1921234Pharmacology & Pharmacy